Position in NVCT
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$10,157
+$237 QoQ
Shares Held
1,314
0.0% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2023
8 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVCT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Ameritas Investment Partners, Inc. holds $51,201,821 across 216 Biotechnology names. NVCT ranks #199 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
12,563 | $5,609,881 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
4,656 | $3,597,411 | |
| 3 | EXEL |
Exelixis, Inc.
|
70,554 | $3,026,060 | |
| 4 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
36,974 | $2,318,269 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
83,064 | $2,300,872 | |
| 6 | CYTK |
Cytokinetics Inc
|
32,284 | $2,127,838 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
11,194 | $2,116,225 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
35,392 | $1,999,294 |
All Filings in NVCT
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $10,157 | 1,314 | Shares | Other | 2026-05-13 | |
| 2025-12-31 | $9,920 | 1,314 | Shares | Other | 2026-02-11 | |
| 2025-09-30 | $7,910 | 1,314 | Shares | Other | 2025-11-10 | |
| 2025-06-30 | $9,815 | 1,314 | Shares | Other | 2025-08-12 | |
| 2024-03-31 | $4,641 | 566 | Shares | Other | 2024-05-13 | |
| 2023-12-31 | $4,720 | 566 | Shares | Other | 2024-02-14 | |
| 2023-09-30 | $7,295 | 566 | Shares | Other | 2023-11-13 | |
| 2023-06-30 | $9,039 | 566 | Shares | Other | 2023-08-11 | |
| No filing history on record for this holder in this stock. | ||||||